Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tecarfarin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Collaboration
Espero BioPharma, Inc. Expands Collaboration Effort for Tecarfarin
Details : Tecarfarin is a Phase III-ready, vitamin K antagonist, taken once a day as an oral anticoagulant like warfarin, but targets a metabolic pathway that is distinct from the one targeted by the most commonly prescribed anticoagulants.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 06, 2020
Lead Product(s) : Tecarfarin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Collaboration